Emerging trends in control and regulation of immunotherapy cellular starting materials
Cell & Gene Therapy Insights 2021; 7(2), 211–221
Published: 19 March 2021
Nathan Manley, PhD is a principal consultant at Dark Horse Consulting with over 17 years of experience in stem cell biology, neuroscience, and preclinical modeling of human disease. Prior to joining Dark Horse, he led research and preclinical development efforts at Asterias Biotherapeutics, a pluripotent stem cell-based biotech company, and trained as an academic researcher in the departments of Biology and Neurosurgery at Stanford University. Over the course of his career, Manley has contributed to the advancement of a wide range of experimental and clinical-stage cell therapy products, authored scientific articles, and co-authored cell therapy patent applications. He also is a part-time instructor in the Biology Department at San Jose State University.